AGILeBiotics is a early-stage pharmaceutical company, which is covering all expertise and knowledge required for the development of novel antibiotics thanks to regional, national and international collaborations with industry and academic institution.
Knowledge in Microbiology and Bacterial Resistance is provided through the participation of our company in the health-i-care program. Within this program, we collaborate with the University Medical Center Groningen (Groningen, NL), the University Hospital Muenster (Muenster, Germany), and the Hopsital Olderburg (Olderburg, Germany).
Design of Novel Antibiotics and Pre-Clinical Development of our antibiotic candidates is supported by close collaborations with the DWI Leibniz Institute for Interactive Materials and the drug discovery service company Integrex Research.
Specialized Synthesis of Antibacterial Compounds is being performed together with the contract research company Syncom BV, which is highly experience in lead-optimization programs and multistep synthesis of natural product inspired lead compounds.
This unique set up facilitated not only the start of our drug discovery program, but now accelerates also the pre-clinical development of our antibiotic candidates
AGILeBiotics is a spin-off company of the University of Groningen located in the North of the Netherlands. The company is located in the InnoLab Chemie that offers state of the art laboratory facilities for start-up companies. All technologies AGILeBiotics is employing were co-invented and established by the CEO of AGILeBiotics Dr. Andreas A. Bastian during his academic career. Collaborating together with the DWI Leibniz Institute for Interactive Materials and the University Medical Center Groningen (UMCG), AGILeBiotics is developing its own drug pipeline of novel antibiotics to treat multidrug resistant infections.
AGILeBiotics is committed to contribute to the fight against antimicrobial resistance by bringing new therapeutic solutions to patients infected by multidrug resistant pathogens. Our vision is to accelerate the development of novel antibiotics by employing smart technologies on existing antibiotic classes, which are based on natural products, and give them a second life cycle on the antibiotic market.
According to the latest reports of the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA), we are entering the post antibiotic era, due to insufficient discovery and development of new antibiotics. The continuous emergence of bacterial resistance against existing antibiotics is life threatening to society. Without acceleration of antibiotic development, death rate will increase by 10-fold by 2050, reaching 250,000 in Europe and 10 million deaths worldwide. The society is running out of treatment options especially against multidrug resistant (MDR) bacteria, which belong to the alarming ESKAPE panel: Enterococcus faecium(+), Staphylococcus aureus(+), Klebsiella pneunomiae(-), Acinetobacter baumannii(-), Pseudomonas aeruginosa(-), Enterobacteriaceae spp.(-). Unfortunately, antibiotic development takes still 10 to 15 years, and most new antibiotic candidates fail in clinical trials due to toxicity and safety reasons. Reviving an existing class of antibiotics is still the most efficient and promising strategy to bring novel antibiotics to the market. This approach evades the discovery stage and increases significantly the success rate during clinical trials. And this is where AGILeBiotics steps in: Our synthetic technologies accelerates the optimization of existing antibiotics, which are based on structurally complex natural products. We employ antibiotics, that are losing their efficacy due to bacterial resistance, to develop novel antibiotics against life-threatening infections caused by MDR bacteria.